Imagion Biosystems Limited appointed Farideh Bischoff, PhD, as the company's Vice President of Clinical Research. Dr. Bischoff will lead the clinical program for the company's MagSenseTM cancer detection technology, working to achieve regulatory approval as a diagnostic device for the early detection of malignant tumor cells. Dr. Bischoff adds a wealth of relevant experience in oncology product commercialisation to the leadership team at Imagion Biosystems. Her accomplishments include scientific development, regulatory submission and successful commercialisation of molecular diagnostics for Biocept. She has led numerous productive collaborative studies, including the NIFTY NIH Fetal Cell Study, composed of individuals from academic, pharmaceutical and biotech organisations. She is widely recognised in the fields of rare cancer cell detection, molecular cytogenetics, diagnostic assay development and validation.